.png){kind=icon}
.png){kind=icon}
Return
Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials
.png){kind=icon}
OA
AI
A
L
S
J
R
DOI：10.1016/j.ajo.2026.06.002.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Microperimetry increases eligibility in RPGR gene therapy trials • LLVA underestimates treatment response across disease stages • Microperimetry detects more responders than LLVA at Month 12 • Central 16-point grid performs comparably to full 68-point testing but must be utilized with caution • Endpoint choice substantially alters detection of trial efficacy
Keywords:
Retinitis Pigmentosa
outcome measure
low luminance visual acuity
microperimetry
Fundus controlled perimetry
endpoint
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.2
Papers:
3.0W
Citations:
2.8W
Organization
Cited Papers